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The conventional view of AD (Alzheimer’s disease) is that much
of the pathology is driven by an increased load of β-amyloid
in the brain of AD patients (the ‘Amyloid Hypothesis’). Yet,
many therapeutic strategies based on lowering β-amyloid have
so far failed in clinical trials. This failure of β-amyloid-lowering
agents has caused many to question the Amyloid Hypothesis
itself. However, AD is likely to be a complex disease driven by
multiple factors. In addition, it is increasingly clear that β-amyloid
processing involves many enzymes and signalling pathways that
play a role in a diverse array of cellular processes. Thus the
clinical failure of β-amyloid-lowering agents does not mean
that the hypothesis itself is incorrect; it may simply mean that
manipulating β-amyloid directly is an unrealistic strategy for
therapeutic intervention, given the complex role of β-amyloid
in neuronal physiology. Another possible problem may be that
toxic β-amyloid levels have already caused irreversible damage
to downstream cellular pathways by the time dementia sets in.
We argue in the present review that a more direct (and possibly
simpler) approach to AD therapeutics is to rescue synaptic
dysfunction directly, by focusing on the mechanisms by which
elevated levels of β-amyloid disrupt synaptic physiology.
Key words: Alzheimer’s disease, β-amyloid, hippocampus,
neuropathology, synaptic.
THE HISTORY OF THE AMYLOID HYPOTHESIS
Alois Alzheimer gave a lecture in 1906 that detailed the cognitive
decline and resulting neuropathology in a 51-year-old woman
named Auguste D [1]. In his subsequent papers [2,3], he
described the extracellular plaques which have come to be
seen as a histological hallmark of AD (Alzheimer’s disease).
The extracellular plaques were subsequently found to have
β-amyloid protein as their major component [4,5], and in
the ensuing decades a massive research effort has focused on
understanding the physiology of this putative disease-causing
protein. Understanding the pathogenesis of AD has become
particularly urgent because of the rapidly aging world population
and the realization that AD causes the overwhelming majority of
dementia cases in the elderly [6,7].
β-Amyloid protein is derived from APP (amyloid precursor
protein). Initial work found that APP is capable of being processed
by two different enzymes; α-secretase and BACE (β-secretase)
(Figure 1; see [8] for a thorough review). The N-terminal
fragments generated from this initial cleavage are called sAPP-α
and sAPP-β respectively, and the C-terminal fragments generated
by α-secretase and BACE cleavage are called C83 and C99
respectively. In both cases, the C-terminal fragment undergoes
a subsequent additional cleavage event by an enzyme complex
called γ -secretase [made up of PS (presenilin) 1 or 2, nicastrin,
PS enhancer 2 and anterior pharynx defective 1]. This second
cleavage results in a fragment called the AICD (APP intracellular
domain), and either the p3 protein in the case of the α-secretase
pathway or the β-amyloid protein in the case of the BACE
pathway. Thus β-amyloid protein results from a proteolytic
cascade involving multiple enzymes and associated by-products.
Around the same time as the discovery that β-amyloid was
the major component of the amyloid plaques in AD, a search
began to find a genetic cause of the disease. After several decades
of research, it has become increasingly clear that AD can be
broken down into two types. On the one hand are cases caused
by mutations that are passed down in a Mendelian fashion. These
cases usually occur before the age of 65 and constitute 1–6%
of all AD cases [9,10]. On the other hand are the remaining
94–99% of all AD cases, which generally occur after the age
of 65 and have a weak association with a wide range of genes,
most notably APOE (apolipoprotein E) [11]. Despite the fact that
only 1–6% of AD cases are caused by a Mendelian mutation,
the rare cases where this was true generated great excitement,
as well as hope that studying the unfortunate families with these
mutations would shed light on the pathogenesis of the disease in all
cases. After a great deal of effort many disease-causing mutations
have been found, and virtually every mutation that causes AD
involves APP itself or subsequent APP processing [9]. The three
main genes involved in familial AD cases are APP and the two
γ -secretase components PS1 and PS2. These mutations affect
APP processing in a way that either increases the overall amount
of β-amyloid production or increases the relative fraction of the
42-amino-acid variant of β-amyloid protein (β-amyloid42 is the
primary component of the β-amyloid plaques in AD) [9,10,12].
These discoveries fuelled the Amyloid Hypothesis, which states
that β-amyloid deposition is a central event in the aetiology
of AD [13]. This hypothesis (as it was originally stated), also
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Figure 1 Amyloid β-protein generation by normal proteolytic processing
of β-APP
APP is shown at the top, with the β-amyloid region in red. APP can be processed through
two mutually exclusive pathways. The α-secretase pathway involves an initial cleavage by
α-secretase which goes through the β-amyloid region, precluding further processing that can
yield β-amyloid. This initial cleavage event releases sAPP-α into the cytosol, and leaves behind
the membrane-bound C83 protein. Processing of C83 by γ -secretase yields the p3 fragment and
the AICD. β-Secretase cleavage of APP yields sAPP-β and C99, and subsequent processing of
C99 yields β-amyloid and the AICD fragment.
suggests that β-amyloid deposition leads to tau pathology and
cell death, and that understanding this cascade could facilitate
rational drug design [13]. This world view is not only consistent
with the known familial cases of AD, but also meshes nicely with
the observation that patients with Down’s Syndrome (trisomy 21)
who live long enough will usually develop AD [14]. Since the APP
gene is located on chromosome 21 (and AD is allegedly caused by
increased β-amyloid levels), a gene-dosing effect could explain
the phenomenon.
Subsequent studies demonstrated that the levels of β-amyloid
found in AD are in fact toxic to neurons [15–17], confirming the
genetic evidence. The mounting evidence in favour of the Amyloid
Hypothesis also had the effect of somewhat marginalizing the
tau-centric view of AD. This view focuses on neurofibrillary
tangles as the aetiological agent in AD. Neurofibrillary tangles
are the other pathological hallmark of AD described by Alois
Alzheimer; they are intracellular (intraneuronal) flame-shaped
inclusions that are relatively insoluble and are positive on
silver staining. These tangles were subsequently found to be
composed predominantly of tau protein [18], which normally
binds to and stabilizes microtubules. The so-called ‘Tauists’
were long at odds with the ‘Baptists’ who believed in a β-
amyloid-centric view of AD [19]. One of the main arrows in the
Tauist quiver has always been that the pathological progression
of tau-containing neurofibrillary tangles in the brain correlates
with the progression of dementia much better than the relative
deposition of β-amyloid plaques [20]. However, the genetic
evidence from familial cases of AD is overwhelmingly in favour of
the Amyloid Hypothesis. Furthermore, disease-causing mutations
in tau were eventually found that cause neurodegeneration, but
they do not cause AD. That is to say, mutations in tau can
cause neurodegeneration with neurofibrillary tangles, but no β-
amyloid plaques [21]. However, mutations that effect β-amyloid
processing cause neurodegeneration with both β-amyloid plaques
and tau-containing neurofibrillary tangles, identical with sporadic
AD found in the general population [9]. Thus it was concluded
that AD is caused by β-amyloid deposits, which cause damage
upstream of tau-positive neurofibrillary tangle deposition [13].
Despite the evidence in support of the Amyloid Hypothesis,
drugs that are based on this hypothesis have had a poor track
record [22]. One popular strategy has been to develop compounds
that modulate or inhibit γ -secretase; the idea is to inhibit the
production of β-amyloid at the final cleavage step (see Figure 1).
This strategy has gained particular popularity given the historical
difficulty in developing good BACE inhibitors [23]. Semagacestat
is so far the most well-known γ -secretase inhibitor to have
been studied extensively in AD trials [24]. Semagacestat can
reduce CNS (central nervous system) β-amyloid production in
healthy volunteers in a dose-dependent manner [25]. However,
two large Phase III trials with over 2600 participants were recently
discontinued after failure to demonstrate efficacy. Compared with
placebo, patients receiving semagacestat actually did worse both
in cognition and in daily function, and were at a higher risk of
developing skin cancer [26].
Another strategy using the Amyloid Hypothesis has focused
on inhibiting oligomer formation. Recent evidence suggests
that the neurotoxic form of β-amyloid is soluble oligomers
of β-amyloid, rather than either monomers or the fibrillar β-
amyloid found in plaques [27–29]. Thus compounds have been
explored that inhibit or destabilize oligomer formation. In pre-
clinical studies, tramiprosate reduced plaque levels in the mouse
brain and plasma by preventing the β-amyloid conformational
changes necessary for oligomer and fibril production [30].
However, in a Phase III study, 1052 AD patients showed no
overall significant differences on the ADAS-cog (AD assessment
scale-cognitive), although there was some improvement on
individual cognitive measures [31]. Other compounds are
currently being developed that inhibit β-amyloid aggregation,
notably scyllo-inositol. This compound reduces brain β-amyloid
concentrations and plaque burden, preserves synaptic density, and
improves learning deficits in transgenic animals [32,33], but a
recent Phase II study revealed no significant differences between
the treatment groups and the control group on two measures of
cognitive function [34]. However, another aggregation inhibitor
(PBT2) has also completed a recent Phase II trial, and patients
taking this compound did show significant improvements in two
measures of executive function [35]. Thus the anti-aggregation
strategy may still hold promise.
Finally, clearance of β-amyloid via the immune system is
currently a popular strategy. There are two ways to do this; active
immunization using an epitope that generates an immune response
to β-amyloid, or passive immunization using direct administration
of anti-β-amyloid antibodies. The active immunization approach
has lost some popularity after an early-stage clinical trial found
meningoencephalitis in the vaccinated patients [36]. There are two
ongoing passive immunization trials in the late stage of Phase III
testing, Bapineuzumab and Solanezumab; both studies have Phase
III results that can be expected at some point in the next year [37–
39]. Solanezumab has so far shown some toxicity advantages to
Bapineuzumab, in so far as Bapineuzumab has caused cerebral
oedema and micro-haemorrhages in some patients, whereas these
toxic effects are not seen in Solanezumab. This difference may
be due to the fact that Solanezumab preferentially binds soluble
β-amyloid, whereas Bapinezumab also binds fibrillar β-amyloid.
This predilection of Bapinezumab for fibrillar β-amyloid may
cause bleeding because the antibodies will not only react to
β-amyloid plaques, but also to cerebral vessels affected by
cerebral amyloid angiopathy (a common vasculopathy in AD
patients where β-amyloid is deposited in cerebral blood vessels).
In any case, in terms of therapeutic efficacy, the jury is still out on
both therapies, as neither one has shown efficacy in Phase II trials.
In a Phase II trial of Bapinezumab, no significant differences were
found in the cognitive status of the treatment compared with the
control group, although exploratory analyses showed a potential
effect on cognitive and functional endpoints in study ‘completers’
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and APOEε4 non-carriers [37]. Solanezumab has also shown no
significant cognitive change compared with the controls in a Phase
II trial, although this trial may not have been sufficiently powered
for efficacy [40]. In any case, the Phase III trial data will be in
soon for both compounds.
A CLOSER LOOK AT β-AMYLOID
When do β-amyloid levels increase in AD patients?
Is β-amyloid accumulating in the brain during a prodromal
(asymptomatic) early phase of AD? This question is particularly
relevant for therapies that target β-amyloid, as these therapies
may fail because they are given too late in the disease course.
However, they may be quite effective early on when β-amyloid
is accumulating and initiating damage in the nervous system.
One of the initial roadblocks with answering this question is
defining what ‘early AD’ is. Of course, to answer this question,
one must first define what AD itself is. Although this may seem
relatively straightforward, the task is made difficult by the fact
that memory can decline for a variety of reasons during aging,
and that elderly people can have β-amyloid pathology in the
absence of any cognitive impairment [41]. These facts have long
confounded the Alzheimer’s field, and made it difficult to draw
a clear line between ‘normal aging’ and ‘AD’. Nevertheless,
in 1984, clinical guidelines for AD were established by a joint
commission of the NINCDS [National Institute of Neurological
and Communicative Disorders and Stroke; now NINDS (National
Institute of Neurological Disorders and Stroke)] and the ADRDA
(Alzheimer’s Disease and Related Disorders Association; now
the Alzheimer’s Association) [42]. These guidelines state that
for a diagnosis of ‘probable’ AD, one must have a clinical
diagnosis of dementia, with deficits in two or more areas, an
onset after the age of 40, a gradual decline in memory and no
alteration in consciousness or evidence of some other medical
condition that could cause the observed deficits in cognition.
The term ‘definite’ AD was reserved for people with autopsy-
confirmed plaques and tangles, so that ‘AD’ was defined as a
clinical-pathological entity (i.e. both dementia in life and the
characteristic pathology at death is required for the diagnosis).
The clinical criteria to diagnose probable AD continued to be
refined over the years by additional expert panels, including an
early panel organized by the NIA (National Institute on Aging)
[43], a panel organized by the CRAD (Consortium to Establish
a Registry for AD) [44], and a panel organized by the NIA and
the Alzheimer’s Association (the NIA-Reagan Institute criteria)
[45]. The original 1984 guidelines are largely still used, with
a recent update that incorporates research into AD biomarkers
[46]. Despite the difficulty of clinically diagnosing AD, the 1984
clinical guidelines correlate well with post-mortem Alzheimer’s
pathology (plaques and tangles), with sensitivity and specificity
both approaching 90%, depending on the threshold of pathology
and the strictness of exclusion criteria for vascular pathology [47].
However, this still provides a substantial 10%window for patients
to be falsely labelled (or not labelled) with AD. Furthermore, the
diagnostic success implied by these figures should be tempered
by the fact that up to 70% of all dementia in the elderly is thought
to be related to AD pathology [7].
If defining AD is difficult, defining early (or non-demented)
AD is even more so. It has long been recognized that elderly
people can develop cognitive impairment that does not meet the
formal definition of dementia, and the concept of MCI (‘mild
cognitive impairment’) was originally developed to describe this
phenomenon [48,49]. Patients with the ‘amnestic’ variant of MCI
(where memory is affected) progress to AD at a rate of 10–15%
per year [50,51], so the concept does have some clinical relevance.
Nevertheless, the diagnosis of MCI is somewhat subjective, as
it relies heavily on self-reporting by the patient (or reporting by a
relative/family member). In addition, MCI may be diagnosed by
a clinician if subtle cognitive impairment is found in an elderly
patient that is more than would be expected given the patient’s
age and education level. However, strict criteria for diagnosing
MCI by a clinician remain to be formally established {although
a recent NIA-AA (Alzhemier’s Association) workshop has made
substantial progress on this issue [52]}.
In any case, given our current understanding of AD and MCI, is
there evidence of early β-amyloid accumulation before cognitive
symptoms develop? Up until very recently it has been difficult to
directly address this issue, as the only way to assess β-amyloid
content in the brain has been at autopsy. Although it has long
been known that β-amyloid pathology can exist in non-demented
people, one would ideally like to show the initial development of
β-amyloid pathology followed by the development of dementia
in the same person (i.e. β-amyloid pathology is predictive of
dementia). In lieu of a brain autopsy, living AD patients in the
past have had CSF (cerebrospinal fluid) drawn and levels of
β-amyloid and tau measured. In patients already suffering from
AD, measured CSF levels of β-amyloid42 are actually lower
than normal using a variety of methods [53], for reasons that
are unclear. Traditionally, the decrease in β-amyloid42 levels has
been thought to be due to the fact that β-amyloid is forming
fibrils and depositing in plaques, thus ‘removing’ β-amyloid from
the CSF [53]. This can’t be the whole story, however, because
in AD, brain tissue has increased levels of both soluble and
insoluble levels of β-amyloid (including β-amyloid42) [54]. In
any case, CSF tau levels increase in AD [55]. The increase in
tau is not very specific for AD, as CSF tau levels also increase
in other neurodegenerative diseases {such as CJD (Creutzfeldt–
Jakob disease) [56]} as well as in stroke [57]. Thus increased
CSF tau is generally regarded as a marker of neuronal injury in
a variety of diseases. More specific for AD are the CSF levels of
phosphorylated tau, which are also increased in AD, but not in
stroke or CJD [53,57,58].
What about MCI? These patients also show low levels of β-
amyloid, and recent evidence has shown that low β-amyloid CSF
levels not only predict the development of AD, but also may
precede the increase in CSF phosphorylated tau levels [53,59–62].
This supports the Amyloid Hypothesis world-view that β-amyloid
pathology is an upstream event, which subsequently leads to tau
hyperphosphorylation and neurodegeneration.
Recently radiological compounds have been developed that
allow one to visualize fibrillar β-amyloid in the brain, most
notably PiB (Pittsburg compound B) [63]. This technology has
shown the early development of β-amyloid pathology, both
in MCI as well as in healthy controls [64–66]. Interestingly,
radiological evidence of β-amyloid pathology is significantly
higher in patients with amnestic MCI than in patients with non-
amnestic MCI (i.e. cognitive impairment not related to episodic
memory), consistent with the idea that amnestic MCI is a
prodromal stage of AD [64,65,67] (remember that patients with
the ‘amnestic’ variant of MCI progress to AD at a rate of 10–
15% per year [50,51]). In addition, the degree of radiological
β-amyloid pathology correlates with the chance of progressing
from normal cognition to MCI, or from MCI to AD [64–
66], despite the fact that fluctuations in radiological β-amyloid
pathology do not correlate very well with cognitive status [68].
This is consistent with the view that elevations in β-amyloid
are an early event in the pathogenesis of this disorder, and that
subsequent changes in β-amyloid levels do not affect cognition,
especially late in the disease.
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In summary, studies with CSF and β-amyloid-binding
radiological compounds largely support the Amyloid Hypothesis.
However, they suggest that β-amyloid may play an important
role early in the disease, before the development of dementia.
This has important implications for therapeutics based on the
Amyloid Hypothesis, as these drugs may have their maximal
effect if administered at these early stages. To do this effectively
will require reliable ways to diagnose this ‘early’ form of AD
(before dementia sets in). Such a goal is being pursued, but has
not yet been achieved. One should also keep in mind that even if
β-amyloid has an ‘early’ role in AD from a clinical perspective, it
is not necessarily the ultimate ‘cause’ of the disease. Indeed, there
could be many additional factors upstream of β-amyloid that are
influencing the ultimate course of the disease. For example, we
should consider the fact that there could be factors that are playing
a role decades before the development of symptoms, similarly
to the role of trauma in the development of chronic traumatic
encephalopathy [69].
An additional problem one must consider with β-amyloid-
lowering drugs is that β-amyloid results from a proteolytic
cascade involving multiple enzymes and associated by-products,
which in turn affect a multitude of cellular processes. Thus any
therapeutic intervention that affects β-amyloid levels may have
an undesirable side effect as a result of affecting one of these
processes. To give a sense of the complexity of this situation, we
will now briefly summarize the role of a selection of the enzymes
and by-products involved in the generation of β-amyloid which
may have a role in complicating β-amyloid-based therapeutic
strategies.
γ -Secretase
The γ -secretase inhibitors have figured prominently in drug
development, and as such, it is worthwhile taking a moment to
review γ -secretase physiology. The vast literature on γ -secretase
will not be fully discussed in the present review for the sake of
brevity (see [70] for a more extensive review), but a couple of key
features are worth noting. First of all, the γ -secretase complex is
involved in processing a wide range of substrates other than APP;
at least 90 different substrates are currently known, including
APP-like proteins 1 and 2, as well as E-cadherin, neuregulin-1 and
2, Notch, RAGE (receptor for advanced glycation end-products),
and ApoER2 (ApoE receptor 2) [71]. Not surprisingly, a vast range
of cellular processes are affected by the substrates of γ -secretase,
including functions regulating cell fate, adhesion, migration,
neurite outgrowth and synaptogenesis. Despite this diversity,
the targets of γ -secretase often have several things in common.
First, most are single-pass transmembrane proteins, with a large
ectodomain and a cytoplasmic C-terminus that often plays a
role in intracellular signalling. Secondly, the targets of γ -secretase
themselves are often involved in intracellular signalling in a wide
range of events, including events related to neurite outgrowth
and synapse formation that are disrupted in neurodegeneration in
AD [71–73]. Finally, γ -secretase often targets membrane-bound
proteins after cleavage and release of the ectodomain fragment by
a prior enzyme [71,74].
Perhaps the most well-known (and problematic) alternate
substrate of γ -secretase is Notch. Notch is a single-pass
transmembrane protein found in a variety of tissues [75,76].
The extracellular domain on Notch binds to a Notch ligand
(which is usually on another cell), and this triggers cleavage
of Notch by ADAM10 (a disintegrin and metalloprotease 10)
and shedding of the Notch ectodomain into the extracellular
space. This is then followed by γ -secretase cleavage of the
remaining membrane-bound protein and release of the NICD
(Notch intracellular domain) into the cytoplasm, where it
translocates to the nucleus and influences gene transcription
(note the similarity to APP processing). Notch has been found
to be involved in a wide range of different processes involving
cell proliferation, cell death, and acquisition of specific cell
fates [75,77,78]. Notch has also been tied to a wide range of
disorders, such as developmental disorders [76,79,80], vascular
disease {CADASIL (cerebral autosomal dominant arteriopathy
with subcortical infarcts and leukoencephalopathy) [81]} and
cancer [82]. Thus it is perhaps not surprising that γ -secretase
inhibition may have many side effects just through affecting Notch
function alone. One possible strategy may be to develop Notch-
sparing inhibitors of γ -secretase that preferentially inhibit the
ability of γ -secretase to produce β-amyloid without affecting
Notch cleavage [70]. Recently, a novel γ -secretase-activating pro-
tein has been discovered that increases β-amyloid production
through interaction with both γ -secretase and its substrate [83].
Notably, this γ -secretase-activating protein does not affect the
interaction of γ -secretase with Notch. Thus this raises the possi-
bility that one may develop a Notch-sparing γ -secretase inhibitor
by inhibiting this activating protein. The same paper demonstrated
that the drug imatinib was capable of lowering β-amyloid levels
specifically through inhibiting the interaction of this γ -secretase
activating protein with its substrate. Thus this research presents
one possible way to develop a Notch-sparing γ -secretase inhibitor.
It is important to keep in mind, however, that despite the
focus of the drug-discovery community on Notch-sparing γ -
secretase inhibitors, any γ -secretase inhibitor could potentially
have adverse side effects due to the involvement of γ -secretase
with any of the other 90 substrates it interacts with.
AICD fragment
The AICD has been linked to a number of cellular processes
[84,85]. These include the modulation of intracellular calcium and
ATP [86], as well as the regulation of cytoskeletal dynamics
and intracellular trafficking [87]. AICD has also been linked to
the regulation of cell-death pathways [88–90], notably through
activation of FADD (Fas-associated death domain protein) [91].
In addition, AICD mediates cell death through the p53 pathway
[92,93]. Notably, AICD has been shown to directly increase
transcription and production of p53 [93], and AICD-mediated
cell death has been shown to be impaired by p53 deficiency [92].
The AICD fragment has also been implicated in the regulation
of β-amyloid, primarily through the regulation of neprilysin,
one of the main β-amyloid-degrading enzymes [94,95]. Recent
evidence suggests that the AICD fragment binds to the promoter
region of neprilysin, and cells depleted of APP or γ -secretase
components PS or nicastrin show a depleted neprilysin mRNA
and protein levels that is reversible upon complementation by
PS, nicastrin or AICD [96,97]. Thus inhibiting γ -secretase
may have side effects from disrupting the normal physiology
of the AICD fragment, one of which is (ironically) the
down-regulation of one of the prime pathways for β-amyloid
clearance.
BACE
Although no BACE inhibitors have made it to late-stage clinical
trials yet for a variety of reasons, BACE presents an obvious
target to inhibit the production of β-amyloid, and several ongoing
early-stage clinical trials are employing this strategy [23]. As such,
it is worth reviewing the fact that ongoing research suggests that
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BACE may have a large number of substrates other than APP. A
screen for novel substrates of BACE1 (the predominant BACE
isoform in the brain) identified 68 putative BACE substrates
[98]. Most of the potential targets identified by this screen are
type I transmembrane proteins, and most are involved in contact-
dependent intercellular communication. Although the majority of
these targets have not yet been validated (as noted in [99]), a
few have been experimentally tested, including APLP (amyloid
β precursor-like protein) 1 and APLP2 [100–102], low-density
lipoprotein receptor-related protein [103] and the voltage-gated
sodium channel β-subunits [104,105]. BACE1 has also been
shown to be involved in the regulation of myelination via cleavage
of neuregulin-1 [106,107] and neuregulin-3 [108]. Thus putative
BACE inhibitors may run into many of the same challenges
that have plagued γ -secretase inhibitors, although compounds
inhibiting BACE are in a far earlier stage of development.
However, despite some initial setbacks, the limited available
human data from clinical trials on BACE inhibitors suggests that
this strategy may present an exciting additional pathway to treat
AD [109].
sAPPβ
The sAPPβ fragment has not been particularly well studied and,
as such, not as much is known about it [110]. However, BACE
inhibitors would obviously decrease sAPPβ levels, so it is worth
briefly considering what is known about this protein. So far,
sAPPβ has been shown to promote axonal outgrowth [111].
In addition, sAPPβ has been shown to robustly drive neuronal
differentiation of human embryonic stem cells [112]. Thus sAPPβ
may be important for neural growth and differentiation. More
work is needed to understand how inhibiting the production of
sAPPβ might affect patients using BACE inhibitors.
β-Amyloid
Finally, what is the normal physiological role of β-amyloid?
Would depleting the brain of β-amyloid below a certain level
have a detrimental effect in any way? This is an often overlooked
problem, as the Amyloid Hypothesis often assumes that β-
amyloid is a toxic protein that needs to be cleared. However,
β-amyloid is produced in the brain throughout life, and the normal
in vivo concentration in the rodent brain has been estimated to be
in the picomolar range [113]. Therefore the normal physiological
role of β-amyloid should be understood if β-amyloid-lowering
therapy is going to be clinically pursued. Unfortunately, studies
regarding the physiological function of β-amyloid peptides have
been limited. For many years, most researchers assumed that
β-amyloid peptides had no function, a sort of ‘waste’ by-
product of the APP processing with the exception of a few
studies. Picomolar levels of exogenously applied β-amyloid40
have been found to play a neurotrophic role in cell cultures
[15,114], and treatment of hippocampal neural stem cell progeny
with β-amyloid42 induces an increase in the number of
newly generated neurons [115]. β-Amyloid levels are likely
to be regulated by synaptic activity [116–119]. In systems
overexpressing familial AD mutant APP, this release of β-
amyloid has the capacity to depress synaptic function [118].
However, in non-transgenic systems, β-amyloid release may
up-regulate synaptic activity [119–121]. Moreover, the brain
interstitial fluid concentration of β-amyloid seems to be
correlated with neurological status, with β-amyloid concentra-
tions increasing as neurological status improves and vice versa
[122]. Previously, we have demonstrated that low picomolar
amounts of exogenously applied β-amyloid42 enhance synaptic
plasticity and memory [121]. Specifically, we have shown that
low picomolar concentrations of β-amyloid42 (similar to the
concentrations normally found in the brain) cause a marked
increase in hippocampal long-term potentiation, whereas high
nanomolar concentrations lead to the well-established reduction
of synaptic plasticity. In addition, we have shown that picomolar
levels of β-amyloid42 produce a pronounced enhancement of
both reference and contextual fear memory. In subsequent studies,
we have demonstrated the role of endogenous β-amyloid by
showing that both anti-rodent β-amyloid antibody and siRNA
(small interfering RNA) against murine APP reduced LTP
(long-term potentiation) as well as contextual fear memory
and reference memory, and that these effects are rescued by
the addition of human β-amyloid42. This work has been
extended by Puzzo et al. [123] who have demonstrated that
β-amyloid42 acts on hippocampal LTP and reference memory
in a biphasic dose–response curve. In other words, low doses
enhance synaptic plasticity and memory, and high doses inhibit
plasticity and memory, similar to many other hormones that
affect memory. Collectively, these findings strongly support
a model for β-amyloid in which low concentrations play a
positive modulatory role on neurotransmission and memory,
whereas high concentrations play the well-known detrimental
effect culminating in dementia. This positive role for β-amyloid
may complicate therapeutic strategies that reduce β-amyloid if
the normal physiological function of this protein is disturbed.
AMYLOID TOXICITY AT THE SYNAPSE: A SHORTER ROAD TO
VICTORY?
Given that high concentrations of β-amyloid have been shown
to cause synaptic and memory dysfunction [27], and given that
dementia is ultimately the key clinical impairment in patients
with AD, one might ask whether addressing synaptic dysfunction
directly might not be the best therapeutic approach. This is the
approach that our laboratory has taken over the past decade. It is
a relatively simple straightforward solution. First, we identify
molecular pathways involved in synaptic plasticity that are
disrupted by high concentrations of β-amyloid, and then we
intervene to rescue these pathways. Although this approach is
consistent with the Amyloid Hypothesis, it is ultimately agnostic
on whether high β-amyloid levels actually cause AD, or whether
high β-amyloid levels are simply a component of AD that
contribute to dysfunction. Our approach also side-steps the issue
of how to distinguish AD from normal aging (see above). Any
brain that has memory impairment caused by high levels of β-
amyloid will benefit from our approach, regardless of whether or
not the patient formally has AD. On the downside, this approach
may not produce a total ‘cure’ of the disease, as rescuing synaptic
function will probably not completely halt the progression of
degeneration. However, there is mounting evidence that early
synaptic dysfunction may contribute to degeneration [124–
127], so rescuing synaptic dysfunction may not only produce
symptomatic relief, but may also slow the course of the disease.
Furthermore, although there is a gradual physical loss of synapses
in AD [128], recent studies on animal models have highlighted a
discrepancy between behavioural deficits and neuropathological
findings. Specifically, electrophysiological studies on mice that
overexpress β-amyloid show impairment of LTP that does not
correlate with the extent of synaptic loss, amyloid deposition
or cell death [129–131]. In addition, animals without amyloid
plaque deposition have been reported to have behavioural deficits
[132,133]. This is consistent with the idea that β-amyloid itself
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Figure 2 β-Amyloid can inhibit synaptic plasticity through a variety of
mechanisms
CREB phosphorylation may be inhibited through inhibition of the PKA pathway, the Uch-L1
proteasomal system, aberrant calpain activity, or inhibition of the cGK pathway. In addition, high
β-amyloid levels may reduce histone acetylation, which can impair gene expression necessary
for learning and memory. See the text for details.
is disruptive to synaptic physiology even in physically intact
synapses, and gives further support to our approach. In any case, a
complete cure will require a full understanding of the pathogenesis
of AD, and this goal has yet to be achieved. Furthermore, even if
β-amyloid turns out to be the causative agent in AD, developing
drugs that lower β-amyloid load in the brain may be difficult
to develop due to side effect issues, and as we have already
argued, they will probably need to be given early in the course
of the disease to be effective. For all of these reasons, we believe
that rescuing synaptic dysfunction is a viable and straightforward
approach to developing therapies for AD where clinical success
may be easier than strategies based on lowering β-amyloid levels.
We will now describe some of our efforts along these lines. The
results of these studies are summarized in Figure 2.
cAMP/PKA (protein kinase A)/CREB
(cAMP-response-element-binding protein) cascade
LTP is a form of synaptic plasticity that is traditionally broken
down into several components, where the early component is
independent of protein synthesis, and the late component (long-
term maintenance) is dependent on gene expression and new
protein synthesis [134]. The details of the biochemical pathway
mediating the switch from early to late LTP have been worked
out in aplysia and mice [135], and depend on the activation
of the transcription factor CREB by phosphorylation by PKA.
This pathway is well preserved across species, functioning
in olfactory memory in Drosophila as well as hippocampus-
dependent memory in mice [136,137]. We have found that
nanomolar concentrations of β-amyloid42 (a concentration well
below that required to induce cell death) causes a rapid and
sustained decrease in the activity of PKA in cultured hippocampal
neurons and a rapid inhibition of CREB phosphorylation in
response to glutamate stimulation [138]. Furthermore, rolipram
and forskolin, agents that increase the intracellular levels of
cAMP, reverse this inhibition, most probably by favouring the
dissociation of regulatory and catalytic subunits of PKA and
the restoration of PKA activity. This reversal is blocked by H89,
an inhibitor of PKA.
On the basis of these findings, we asked whether rolipram
could exert beneficial effects in the brains of mice carrying both
the mutant APP (K670N,M671L) and PS1 (M146L) transgenes
(APP/PS1 mice), an animal model of amyloid deposition
that partially reproduces the cognitive deficits that occur in AD
patients [139,140]. These mice display impaired LTP, spatial
working memory and contextual learning as early as 3–4 months
of age, and they show deficits in basal synaptic transmission and
spatial reference memory after 5–6 months of age [141]. We found
that the impairment in LTP in APP/PS1 slices was rescued by a
20 min rolipram perfusion prior to LTP induction. We also found
that rolipram injections improve contextual fear conditioning
(a form of hippocampal-dependent fear memory) and spatial
working memory in 3-month-old APP/PS1 mice. In addition,
daily injections of rolipram for 3 weeks in 3-month-old APP/PS1
mice continue to show benefits as the mice age; for example,
improvement in the radial-arm water maze and Morris water maze
performance (measurements of hippocampal-dependent spatial
memory) that are still sustainable at 6–7 months. Furthermore,
LTP impairments in hippocampal slices also remain rescued at
7–8 months of age. These findings are particularly exciting, as
they suggest that the beneficial effect of rolipram administration
can be extended beyond the duration of the administration,
possibly due to stabilization of synaptic circuitry via alterations
in gene expression and activation of the cAMP-dependent protein
kinase (PKA)/CREB signalling pathway. Consistent with this
hypothesis, daily injections of rolipram for 3 weeks in 3-month-
old APP/PS1 mice reverse the decrease in CREB phosphorylation
both in hippocampal extracts and in hippocampal slices from the
same mice at 7–8 months of age.
Is there any downside to chronically increasing CREB
phosphorylation? It is important to note that memory can actually
be impaired if CREB activity is increased too much [142].
Furthermore, CREB itself is involved in a wide range of other
physiological processes [143] and CREB overexpression has
been linked to leukaemia [144]. This has led some to question
a therapeutic strategy based on elevating CREB activity [143].
These are important points. However, they are unlikely to
contradict the strategy we described in the present review. This is
because our goal is not to elevate CREB activity to abnormally
high levels, but rather to return it to its normal level of activity
(i.e. to rescue the decrease in CREB activity seen in AD).
NO/sGC (soluble guanylate cyclase)/cGMP/cGK (cGMP-dependent
protein kinase)/CREB cascade
Hippocampal and cortical LTP have both been shown to involve
nitric oxide (NO) [145,146]. NO is a membrane-permeable gas
that may be involved in CREB phosphorylation [147–149]. NO is
synthesized from L-arginine by the enzyme NOS (NO synthase)
and induces cGMP production through the activation of the
enzyme sGC [150]. cGMP, in turn, activates cGKs, a family of
signal transduction mediators [151], leading to an increase
in CREB phosphorylation during LTP [149]. To determine
whether NO plays a beneficial effect on β-amyloid-induced
reduction of LTP, we used the NO donor DEA/NO
(diethylamine NO) and found that it rescues LTP impairment
in hippocampal slices perfused with β-amyloid42 [152]. We
then explored several steps downstream of NO production.
The following compounds all rescued LTP impairment in
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hippocampal slices perfused with β-amyloid42: BAY41–2272 (a
sGC stimulator), and both 8-Br-cGMP and 8-pCPT-cGMP (cGMP
analogues). Another important finding of our experiments was
that the increase in cGMP levels, normally occurring immediately
after tetanic stimulation [153], is blocked in β-amyloid42-treated
slices. This finding indicates that β-amyloid42 directly interferes
with the NO/cGMP/cGK/CREB pathway to suppress LTP.
We also showed that β-amyloid42 blocks an increase in CREB
phosphorylation during LTP, and that application of an NO donor,
an sGC stimulator, or cGMP analogues re-establishes normal
levels of phospho-CREB during potentiation in a high β-amyloid
environment. Most importantly, the effect of cGMP analogues
on CREB phosphorylation and LTP was specifically mediated
through cGK, because treatment with the cAK (cAMP-dependent
protein kinase) inhibitor KT57230 did not suppress the beneficial
effect of cGMP analogues, as occurred with the cGK inhibitor
KT5823. Our study suggests that intervention using NO donors
or drugs enhancing cGMP levels may ameliorate cognitive deficits
in patients affected by AD and other neurodegenerative diseases
characterized by abnormal production of β-amyloid42.
The PDE5 (phosphodiesterase 5) inhibitor sildenafil (popularly
known as Viagra) enhances phosphorylation of CREB through
elevation of cGMP levels. We were curious to see whether this
drug could rescue synaptic plasticity and memory in APP/PS1
mice [154]. We found that: (i) a 10 min perfusion of 3-
month-old APP/PS1 mouse hippocampal slices with sildenafil
reverses CA (cornu ammonis) 1 LTP impairment; (ii) a single
intraperitoneal injection of sildenafil in APP/PS1 mice can fully
rescue associative memory and partially rescue spatial working
memory; and (iii) daily injections of sildenafil for 3 weeks
in 3-month-old APP/PS1 mice improve both associative and
spatial memory (both short- and long-term) in 6–8-month-old
APP/PS1 mice, and also rescues LTP in hippocampal slices from
these same mice. Thus the therapeutic effects of sildenafil (like
rolipram) persist long after the drug has been given. We also
found that sildenafil re-establishes the normal increase in CREB
phosphorylation after tetanic stimulation in APP/PS1 mice, and
also reduces β-amyloid levels in these same mice. Sildenafil is
currently on the market (Viagra), and its relatively mild side-
effect profile is well known. Thus this compound or, even better,
other compounds with PDE5-inhibitory activity and improved
toxicity profile and pharmacokinetic characteristics are excellent
candidates for therapeutic intervention in AD. Our laboratory
is currently developing novel PDE5 inhibitors that are highly
blood–brain barrier permeant and are tailored for the chronic
administration to a senile population.
Calpains
At least 14 mammalian calpains, cytosolic calcium-activated
cysteine proteases, have been identified [155]. Two major forms,
calpain 1 and calpain 2, also known as μ-calpain and m-
calpain, have been linked to AD [156]. Calpain 1 is the form
most concentrated in synapses [157] and is abnormally activated
in AD brain [158]. Calpastatin, the endogenous inhibitor of
calpains, is significantly decreased in AD as well [156]. The
activated form of calpain 2 is increased in neurites of neurons
at risk for developing neurofibrillary pathology and is extensively
bound to neurofibrillary tangles in brains of AD patients [159].
Calpain overactivation is triggered by abnormally high calcium
levels; this and calpastatin depletion leads to limited cleavage
or degradation of key neuronal proteins in AD [156,160].
Indeed, calpains modulate the trafficking and, indirectly, the
proteolytic processing of the APP [161–165]. Moreover, calpains
influence the phosphorylation and proteolysis of tau (the major
component of neurofibrillary tangles) [155,160]. Other calpain
substrates affected in AD include CaMK-IIα (CaM-kinase IIα)
and PKC (protein kinase C) [166–168], second-messenger-related
enzymes such as phospholipase C-1, -2 and -β3 [169], and
Cdk-5 (cyclin-dependent kinase 5) [170], transcription factors
such as c-Jun, c-Fos and IκB (inhibitor of nuclear factor κB)
[171,172], and CREB [138,152,173]. Calpains also regulate
cytoskeletal proteins such as spectrin [174] and MAP2 [175]
and, through direct proteolytic actions and indirect modulatory
effects on several protein kinases [PKC, ERK1/2 (extracellular-
signal-regulated kinase 1/2), CaMK-II and Cdk-5/p35], play a
key role in regulating the dynamic behaviour and turnover of
cytoskeletal proteins, especially those in synapses where calpain
concentrations are high [157]. Recently, calpain actions on the
GluR1 subunit of AMPA receptors [176], amphiphysin I [177] and
suprachiasmatic nucleus circadian oscillatory protein [178], have
been shown to modulate synaptic activity and memory formation.
Given the role of deranged calpain activity in synaptic
dysfunction in AD, we investigated the role of calpain inhibition
on synaptic function and memory in APP/PS1 mice [179].
We found that the cysteine protease inhibitor E64 and the
more specific calpain inhibitor BDA-410 re-established normal
synaptic function [mEPSC (miniature excitatory postsynaptic
current) frequency] in APP/PS1 mouse hippocampal cultures,
rescued LTP in APP/PS1 hippocampal slices, and rescued
associative memory, spatial working memory and long-term
spatial memory in APP/PS1 mice. Calpain inhibition also
re-established the increase in CREB phosphorylation during
synaptic plasticity in APP/PS1 mice and produced a normal
distribution of the synaptic protein synapsin I. Thus calpain
inhibition is another method of therapeutic intervention that
restores synaptic function in AD. To this end, our laboratory is
synthesizing specific calpain inhibitors tailored to CNS diseases
and chronic administration to a senile population.
Other targets
Uch-L1 (ubiquitin C-terminal esterase L1)
The brains of AD patients show an accumulation of
ubiquinated proteins [180], suggesting inhibition of the protein
degradation machinery. Interestingly, Uch-L1, a neuron- and
testis-specific enzyme, is down-regulated in AD brains. AD
brains show prominent Uch-L1 immunostaining associated with
neurofibrillary tangles, and levels of soluble Uch-L1 are inversely
proportional to the number of tangles [181]. A possible link
between Uch enzymes, memory and AD is suggested by the
requirement for Uch in long-term facilitation in Aplysia [182], by
reports of decreased levels of Uch-L1 in post-mortem AD brain
[181], and by β-amyloid aggregates and intraneuronal ubiquitin
deposits in gad (gracile axonal dystrophy) mice that lack Uch-
L1 activity [183,184]. We have investigated the role of Uch-L1
reduction in synaptic dysfunction in AD [185]. We have shown: (i)
a reduction of soluble Uch-L1 protein levels in the hippocampus
of APP/PS1 mice; (ii) that inhibition of Uch-L1 activity leads
to the inhibition of hippocampal LTP; and (iii) that transduction
of Uch-L1 protein restores LTP in APP/PS1 mice and also re-
establishes normal Uch activity, basal neurotransmission and
synaptic plasticity, and improves associative memory in mice.
Uch-L1 has also been shown to be associated with Parkinson’s
disease. Lansbury and colleagues have shown that C-terminal
farnesylation promotes the association of Uch-L1 with cellular
membranes, such as the endoplasmic reticulum, and that the levels
of this membrane-associated Uch-L1 correlate with α-synuclein
pathology in transfected cells [186]. Furthermore, a reduction in
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membrane-associated Uch-L1 levels with a farnesyltransferase
inhibitor reduces α-synuclein levels and increases cell viability in
cell culture, suggesting that this may be a successful therapeutic
approach in Parkinson’s disease and other synucleinopathies. It
is unclear exactly how membrane-associated Uch-L1 promotes
α-synuclein pathology, although one hypothesis may be that
membrane association reduces the pool of soluble Uch-L1
that is involved in α-synuclein degradation.
We have previously proposed a model where a fall in cAMP
shifts the equilibrium of the PKA complex towards the inactive
form [bound to the PKA-R (PKA regulatory subunit) protein],
resulting in decreased CREB phosphorylation and transcription
[138]. We asked whether the effect of Uch-L1 on β-amyloid-
induced synaptic dysfunction is associated with this PKA complex
equilibrium. Our hypothesis is that Uch-L1 degrades the PKA-R
protein, freeing up PKA to activate CREB. Therefore, when Uch-
L1 levels fall, PKA-R is not degraded, PKA is sequestered and
CREB phosphorylation is impaired. We first treated hippocampal
slices with 200 nM β-amyloid for 20 min and found PKA activity
reduced by 30%. Pre-treatment with 20 nM Uch-L1 for 1 h
before applying β-amyloid blocked the reduction. Furthermore,
PKA-RIIa subunit levels in hippocampal slices were increased
after exposure to β-amyloid, and this increase was blocked by
pretreatment with Uch-L1. Finally, treatment with β-amyloid
blocks the increase in phosphorylated CREB induced by theta
burst in hippocampal slices; this inhibition is reversed by Uch-L1
pretreatment. Later work has demonstrated that Uch-L1 treatment
can restore spine density to near control conditions in mouse
models of AD, and that this effect is seen even in elderly mice
[187]. Thus up-regulating Uch-L1 activity is another possible
therapeutic strategy for rescuing synaptic function, both in AD
and in other neurodegenerative diseases [188]. Although the above
discussion focuses on Uch-L1, the ubiquitin–proteasome system
is widely studied as a target for therapeutic intervention in AD,
such as recent work by Pasinetti and colleagues showing that this
system may regulate levels of BACE in AD [189].
Epigenetic mechanisms
The use of HDAC (histone deacetylase) inhibitors in rodents
has demonstrated the role of chromatin modification in the
transcriptional regulation of processes underlying memory. A
cursory review of the literature reveals that HDAC inhibition can
increase both learning and hippocampal LTP in association with
a selective increase in histone acetylation [190–193]. Also, in
neuropathological models, a role for the epigenetic modulation of
memory and learning has been proposed [194]. Specifically, levels
of CBP (CREB-binding protein; a histone acetyltransferase driven
by CREB that is involved in learning and memory) are reduced in
mice lacking functional PS1 and PS2 [195]. Moreover, wild-type
PS1 stimulates CBP transcriptional ability, whereas a PS1 mutant
does not have this effect [196]. Additionally, CBP overexpression
ameliorates memory deficits in a mouse model of AD [197].
Most importantly, we have found that Aβ reduces hippocampal
levels of CBP and PCAF (p300/CBP-associated factor), two HATs
(histone acetyltransferases) that are relevant to memory formation
[191,198,199].
We have shown that a brief HDAC inhibition enables the
recovery of impaired memory in APP/PS1 mice through histone
epigenetic modification [200]. Specifically, we observed that
APP/PS1 mice display a reduced endogenous level of H4
acetylation after a learning task. Nevertheless, the acute exposure
to a class I/II HDAC inhibitor, TSA, rescued contextual spatial
learning and hippocampal CA3–CA1 LTP, as well as H4
acetylation in APP/PS1 mice. Our results suggest that these effects
from TSA are likely to be mediated, at least in part, by the re-
elevation in H4 acetylation (hyperacetylation), which might be
low as a consequence of either reduced endogenous HAT activity
or increased endogenous HDAC activity following overexpression
of the APP and PS1 transgenes. In addition, inhibition of HDACs,
particularly HDAC2, also reinstates learning and long-term
memory in other mouse models of neurodegeneration [201–203].
Thus these findings demonstrate a possible epigenetic component
to synaptic dysfunction in AD.
CONCLUSION
The Amyloid Hypothesis of AD is supported not only by
genetic evidence in familial cases, but is also supported by our
increasingly sophisticated understanding of the pathogenesis of
AD in non-familial cases. Although it is true that amyloid plaques
do not correlate well with the course of the disease at later
stages, various biomarkers do suggest that amyloid pathology
correlates with progression at earlier stages of the disease. This
is in keeping with our understanding of the role of β-amyloid
in disease pathogenesis. Nevertheless, therapies based on the
Amyloid Hypothesis have a poor track record to date. We believe
that several impediments need to be overcome before β-amyloid-
lowering therapies will be effective (namely, identifying patients
at the early stage of the disease and achieving lower β-amyloid
levels without deleterious side effects). In addition, we believe
that further study is warranted on whether β-amyloid is the true
ultimate ‘cause’ of AD or whether there are other factors that are
up-stream of β-amyloid. We believe that an alternative strategy
to lowering β-amyloid levels is to rescue synaptic dysfunction
that results from a high β-amyloid environment. This alternative
strategy is agnostic on whether β-amyloid is the ultimate ‘cause’
of AD or whether β-amyloid is simply a toxic by-product of
an upstream event. In either case, our goal is simply to rescue
synaptic dysfunction that results from high β-amyloid levels.
This goal can be achieved using a number of different strategies
(see Figure 2), and some of the compounds we and others are
currently developing have well-established tolerable side effect
profiles. While an absolute cure for AD should be our ultimate
goal, we believe that a synaptic rescue strategy can bring more
immediate relief to Alzheimer’s patients, before the pathogenesis
of this terrible disease is completely understood. Although this
approach may not produce a total ‘cure’ of the disease, there is
mounting evidence that early synaptic dysfunction may contribute
to degeneration [124–127], so rescuing synaptic dysfunction may
not only produce symptomatic relief, but may also slow the course
of the disease. In addition, we believe that a synaptic rescue
strategy is entirely consistent with the Amyloid Hypothesis if
one looks at this hypothesis from a broader perspective. Just
because β-amyloid is central to AD does not necessarily mean that
decreasing β-amyloid levels is the most effective way to combat
the disease. Rather, going ‘around’ β-amyloid and alleviating its
toxic effects may actually be the best strategy. Thus we believe
that the Amyloid Hypothesis should be viewed more broadly, and
that the AD field should consider alternative ways of treating AD
other than manipulating β-amyloid itself.
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